C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up

Autor:	Li, Ping, Yu, Wen-Juan, Zhou, Lili, Yang, Min, Ye, Shiguang, Zhu, Judy, Huang, Jiaqi, Zhang, Yan, Li, Lanfang, Zhao, Jing, Zhu, Kevin, Li, Jing, Zheng, Chengxiao, Lan, Liping, Wan, Hui, Yao, Yihong, Zhang, Huilai, Zhou, Daobin, Jin, Jie, Liang, Aibin
Zdroj:	In Blood 2 November 2023 142 Supplement 1:1025-1025
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu